– USA, CA – iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the appointment of Quentin Blackford to its Board of Directors as President and CEO, effective October 4, 2021.
“Quentin is a world-class leader who has been at the center of growth and market expansion at multiple premier medtech companies,” said Board Chairman, Abhijit Talwalkar. “Quentin has a strong track record of engaging teams to instill excellence across global operations. He shares our commitment to innovation and appreciates the important role it has in improving lives. We are delighted to welcome him to iRhythm to drive our next phase of growth.”
Douglas Devine will continue to serve as the Interim CEO until Mr. Blackford joins the company on October 4th, 2021.
Mr. Talwalkar added, “We are immensely grateful to Doug for his leadership and steady hand over these past weeks as interim CEO. His commitment to iRhythm and our stakeholders helped ensure a smooth transition period and continued progression on our operating plans. He is a valuable member of our executive management team.”
About Quentin Blackford
Quentin Blackford is an accomplished industry leader, bringing more than 20 years of experience scaling premier innovative medical device and digital health companies, including most recently as COO of Dexcom, Inc., a leader in diabetes care technology. In that role, he was responsible for global operations, corporate strategy, and expansion into new markets, helping guide the company during a period of significant growth and transformation.
“I am excited to be joining iRhythm as CEO,” said Mr. Blackford. “iRhythm’s business is built around innovative technology with differentiated capabilities that providers and patients value. This is a powerful platform for growth and I am looking forward to joining the iRhythm team to help capitalize on the company’s many opportunities.”
Mr. Blackford most recently served as the COO of Dexcom, Inc. In this role, Mr. Blackford was responsible for Dexcom’s global operations, strategic development and growth, and entrance into new markets. He joined Dexcom as CFO in 2017.
Before Dexcom, Mr. Blackford served as NuVasive’s EVP, CFO, Head of Strategy and Corporate Integrity, where he played a key role in navigating the company through phases of significant growth and profitability improvements since 2009. He was instrumental in several acquisitions to build upon NuVasive’s portfolio of products and entry into new product segments, as well as geographic expansion.
Before his roles at NuVasive, Mr. Blackford led the organization’s Global Financial Planning & Analysis group at Zimmer Holdings, Inc., in addition to serving as Director of Finance and Controller of the Dental Division.
Mr. Blackford is an independent member of the Board of Directors of Alphatec Holdings, Inc. and Axogen, Inc.
Mr. Blackford is a Certified Public Accountant (inactive) and received dual Bachelor of Science degrees in Accounting and Business Administration from Grace College.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change the clinical management of patients.
For more information: https://www.irhythmtech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
